Pimozide is not a direct inhibitor of BCR/ABL. (A) K562 and KU812 cells were treated with pimozide (10μM) or imatinib (1μM) for 3 hours, after which immunoblot analysis was performed using antibodies to the phosphorylated forms of ABL1 and STAT5, as well as total ABL1 and STAT5. (B) K562 and KU812 cells were treated with pimozide (10μM) or imatinib (1μM) for 3 hours, after which immunoblot analysis was performed using a pan-antiphospho-tyrosine antibody. (C) K562 cells were treated with pimozide and imatinib for 3 hours, and MAPK activation was measured by immunoblot analysis using an antibody to phosphorylated MAPK and a total MAPK antibody.